(89)Zr-immuno-PET using the anti-LAG-3 tracer [(89)Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC

PURPOSE: Although lymphocyte activation gene-3 (LAG-3) directed therapies demonstrate promising clinical anti-cancer activity, only a subset of patients seems to benefit and predictive biomarkers are lacking. Here, we explored the potential use of the anti-LAG-3 antibody tracer [(89)Zr]Zr-BI 754111...

Descripción completa

Detalles Bibliográficos
Autores principales: Miedema, Iris H.C., Huisman, Marc C., Zwezerijnen, Gerben J.C., Grempler, Rolf, Pitarch, Alejandro Perez, Thiele, Andrea, Hesse, Raphael, Elgadi, Mabrouk, Peltzer, Alexander, Vugts, Danielle J., van Dongen, Guus A.M.S., de Gruijl, Tanja D., Menke-van der Houven van Oordt, C. Willemien, Bahce, Idris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199858/
https://www.ncbi.nlm.nih.gov/pubmed/36859619
http://dx.doi.org/10.1007/s00259-023-06164-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199858/
https://www.ncbi.nlm.nih.gov/pubmed/36859619
http://dx.doi.org/10.1007/s00259-023-06164-w

Ejemplares similares